FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma By Ogkologos - January 10, 2025 804 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR Screen-Detected Colorectal Cancers Have a More Favourable Stage Distribution than Colorectal... May 20, 2022 EMA Recommends Granting a Marketing Authorisation for Aumolertinib January 8, 2026 Trastuzumab Deruxtecan Shows High Intracranial Response Rate in Patients with Active... August 9, 2022 EMA Recommends Extending Indications for Durvalumab July 17, 2025 Load more HOT NEWS CVS, Walgreens, Rite Aid Suspend Sales Of Zantac Following Cancer-Causing Concerns FDA Grants Accelerated Approval to Futibatinib for Cholangiocarcinoma Coping With the Holidays During COVID-19 and Cancer Opinion: “We’ve been pushing for change for 20 years. We’re not...
